Clinical trial
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With…
NCT03081494 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03081494 |
|---|---|
| Title | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer |
| Official title | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | spartalizumab (PDR001), regorafenib |
| Enrollment | 10 |
| Start date | Jun 9, 2017 |
| Primary completion | May 7, 2019 |
| Completion | May 7, 2019 |
| First posted | Mar 16, 2017 |
| Last update posted | Dec 11, 2020 |
| Countries | Australia, Canada, Israel, Italy, Netherlands, Singapore, South Korea, Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: